Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Kirsten
K
Fischer
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Othman
O
Al-Sawaf
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Anna-Maria
AM
Fink
F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
Mark
M
Dixon
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Jasmin
J
Bahlo
F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
Simon
S
Warburton
Moores Cancer Center, University of California San Diego, San Diego, CA.
Thomas J
TJ
Kipps
Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.|Malaghan Institute of Medical Research, Wellington, New Zealand.|Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
Robert
R
Weinkove
Queen Elizabeth II Health Science Center, Halifax, NS, Canada.
Sue
S
Robinson
Department of Internal Medicine III, University Hospital Ludwig-Maximilians University Munich, Munich, Germany.
Till
T
Seiler
Monash Hematology, Monash University, Clayton, VIC, Australia.
Stephen
S
Opat
Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada.
Carolyn
C
Owen
Hospital Ramon y Cajal, Madrid, Spain.
Javier
J
López
F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.
Kathryn
K
Humphrey
AbbVie, Inc., North Chicago, IL.
Rod
R
Humerickhouse
Department of Internal Medicine III, Ulm University, Ulm, Germany.
Eugen
E
Tausch
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Lukas
L
Frenzel
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Barbara
B
Eichhorst
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.|Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
Clemens-M
CM
Wendtner
Department of Internal Medicine III, Ulm University, Ulm, Germany.
Stephan
S
Stilgenbauer
Department of Immunology, Laboratory for Medical Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
Anton W
AW
Langerak
Department of Immunology, Laboratory for Medical Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
Jacque J M
JJM
van Dongen
Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; and.
Sebastian
S
Böttcher
Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; and.
Matthias
M
Ritgen
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Valentin
V
Goede
Genentech, South San Francisco, CA.
Mehrdad
M
Mobasher
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Michael
M
Hallek
D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects
D061067:Antibodies, Monoclonal, Humanized; D019086:Bridged Bicyclo Compounds, Heterocyclic; D013449:Sulfonamides; C579720:venetoclax; C543332:obinutuzumab